Newswire

Health Canada Approves Label Update for AbbVie's HUMIRA® (adalimumab) Supporting Potential For Use During Breastfeeding and Use During Pregnancy if Clearly Needed

MONTREAL, Oct. 15, 2018 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved a label update for HUMIRA® (adalimumab) to ...
Newswire

AbbVie's HUMIRA® (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa

MONTREAL, Jan. 6, 2016 /CNW/ - AbbVie, a global biopharmaceutical company, today announced that Health Canada approved HUMIRA® (adalimumab) for the treatment of adults with active moderate to severe ...